Kyntra Bio Director Jeffrey Edwards Receives 7,000-Share Option Award

What Happened

Jeffrey L. Edwards, a director of Kyntra Bio, was granted a derivative award on 2026-06-12 covering 7,000 shares. The grant is reported at $0.00 per share (no cash paid at grant). This is an award/option-style grant (not an open-market purchase or sale) and represents compensation rather than an immediate market transaction.

Key Details

• Transaction date: 2026-06-12 (reported on Form 4 filed 2026-06-17).
• Transaction type/code: Grant/Award (derivative acquisition), 7,000 shares @ $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The shares subject to the option vest in four equal quarterly installments measured from the date of grant.
• Filing timing: Form 4 filed five days after the grant date (investors may note the gap between grant and filing).

Context

This was an option/award grant that vests over four quarters — it is not an exercise or sale and yields no immediate cash or share sale proceeds. Such grants are commonly part of director compensation; they do not necessarily signal insider buying or selling intentions. Retail investors should view this as a compensation-related issuance that will only convert into exercisable/owned shares as the award vests.